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April 3, 2012:1333–5was assumed that troponin T found in these patients was not of
cardiac origin. However, Ricchiuti et al. (3) reported that cTnT
soforms expressed in renal diseased skeletal muscle will not be
etected by the second-generation cTnT assay. By contrast, the results
rom Jaffe et al. (1) indicate that there are forms in chronic diseased
keletal muscle that could cause significant increases in circulating
TnT levels, and these increases might reflect the re-expressed
soforms that can be detected by the more sensitive assay.
We are unaware of reports on an initial concordant but a late
iscordant cardiac troponin result obtained from the same patient
ith severe acute skeletal muscle injury like rhabdomyolysis.
lthough our study was not performed with the newest cTnT
ssay, the monoclonal antibodies in the third-generation assay used
n our patient are the same that were used in the study by Jaffe et
l. (1). Therefore, our hypothesis is that the re-elevations of cTnT
evels in the subacute phase of rhabdomyolysis found in our study
ight be the result of re-expression of cTnT isoform during the
egeneration of skeletal muscle. In addition, there is the possibility
hat only inflammatory changes or severe damage of skeletal
uscle serve as triggering factors for the re-expressing process,
roducing significant amounts of tissue cTnT that are subse-
uently released into the circulation. Nevertheless, additional
tudies using high-sensitivity cardiac troponin assays are required
o clarify this controversial but important issue.
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Reply
We thank Dr. Sribhen and colleagues for their interest in our
paper (1). It is certainly possible that the situation reported by Dr.Sribhen and colleagues is an example of the phenomenon we
described in our paper. The re-expression of the B chain of
creatine kinase-myocardial band is known to occur in this
situation (2), and it could well be that re-expression of the
proteins that can be measured with the cardiac troponin T
(cTnT) assay we described could also have occurred. However,
other possibilities exist as well. It is known that rhabdomyolysis
can involve the heart (3), and we note with some distress that
the generation of the Ortho assay used to measure cardiac
troponin I (cTnI) and the cutoff values employed are not included in
the Sribhen letter. We and others have worried that on occasions
published reports have been confused by the lack of this type of
information, especially when high cutoff values or insensitive assays
have been used (4). In addition, discrepancies between cTnI and
cTnT are known to occur in both directions (5). It is thus possible
that there was cardiac involvement missed by the cTnI assay.
Collaborative data such as a normal magnetic resonance image
would have been extremely helpful. Finally, increases in cTnT but
only skeletal muscle TnI have been reported previously in patients
with rhabdomyolysis (6). All that said, it is our opinion, assuming
the reasonable use of the cTnI assay, that this case report
represents a case likely due to the phenomenon of re-expression of
protein forms in skeletal muscle similar to what we have described.
The key question is how frequently does this occur?
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